Trade

with

Anacor Pharmaceuticals Inc
(NASDAQ: ANAC)
AdChoices
27.66
-0.58
-2.05%
After Hours :
27.66
0.00
0.00%

Open

28.41

Previous Close

28.24

Volume (Avg)

381.37k (587.86k)

Day's Range

27.25-28.44

52Wk Range

11.34-28.46

Market Cap.

1.16B

Dividend Rate ( Yield )

-

Beta

1.89

Shares Outstanding

42.00M

P/E Ratio (EPS)

17.21 (1.61)

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
  • Management effectiveness
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 17.23M

    • Net Income

    • 84.76M

    • Market Cap.

    • 1.16B

    • Enterprise Value

    • -

    • Net Profit Margin %

    • 355.79

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.89

    • Forward P/E

    • -12.50

    • Price/Sales

    • 62.50

    • Price/Book Value

    • 14.01

    • Price/Cash flow

    • 15.41

      • EBITDA

      • 91.03M

      • Return on Capital %

      • 70.15

      • Return on Equity %

      • 156.72

      • Return on Assets %

      • 70.15

      • Book Value/Share

      • 2.02

      • Shares Outstanding

      • 42.00M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Buy
        • 1 Year Price Target

        • 32.50

        • Credit Rating

        • -

        • Analysts

        • 2

        • EPS Estimate

        • -2.34

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • -14.40

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -7.23

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 82.75

            • Pre-Tax Margin

            • 364.69

            • 39.38

            • Net Profit Margin

            • 355.79

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 100.00

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -85.20

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -87.10

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 0.28

              • 0.76

              • Current Ratio

              • 5.75

              • 2.92

              • Quick Ratio

              • 5.63

              • 2.35

              • Interest Coverage

              • 16.81

              • 38.02

              • Leverage Ratio

              • 1.63

              • 2.21

              • Book Value/Share

              • 2.02

              • 4.75

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • 17.57

                • 277.78

                • P/E Ratio 5-Year High

                • 17.70

                • 634.30

                • P/E Ratio 5-Year Low

                • 1.87

                • 124.82

                • Price/Sales Ratio

                • 62.50

                • 9.35

                • Price/Book Value

                • 14.01

                • 8.50

                • Price/Cash Flow Ratio

                • 15.41

                • 50.25

                • Key Metrics

                • Company

                  • Shares Short

                    as of -

                  • -

                  • Short Ratio

                    as of -

                  • -

                  • Short % of Float

                    as of -

                  • -

                  • Shares Short

                    prior month

                  • -

                  • Trailing Annual Dividend Yield

                  • -

                  • 5 Year Average Dividend Yield

                  • -

                  • Key Metrics

                  • Company

                    • Payout Ratio

                    • -

                    • Dividend Date

                    • -

                    • Ex-Dividend Date

                    • -

                    • Last Split Factor

                      new per old

                    • -

                    • Last Split Date

                    • -

                    • Key Metrics

                    • Company

                    • Industry

                      • Return on Equity %

                        (5-Year Average)

                      • 156.72

                        (-)

                      • 37.63

                        (27.20)

                      • Return on Assets %

                        (5-Year Average)

                      • 70.15

                        (-37.10)

                      • 17.22

                        (13.81)

                      • Return on Capital %

                        (5-Year Average)

                      • 101.46

                        (-)

                      • 21.78

                        (17.31)

                      • Income/Employee

                      • 864.04k

                      • 117.08k

                      • Inventory Turnover

                      • -

                      • 1.48

                      • Asset Turnover

                      • 0.20

                      • 0.55

                      Current Historical
                      Financials
                      • Income Statement
                      • Balance Sheet
                      • Cash Flow
                      Operating Income
                      92.52M
                      Operating Margin
                      537.02
                      Total Equity
                      -
                      Retained Earnings
                      -
                      Free Cashflow
                      -
                      Price/Cashflow
                      15.41
                      Ownership

                      Institutional Ownership

                      94.69%

                      Top 10 Institutions

                      48.57%

                      Mutual Fund Ownership

                      30.28%

                      Float

                      78.59%

                      5% / Insider Ownership

                      2.65%

                      Corporate insiders or major stockholders reporting trading activity in the stock.

                      Top Mutual Fund Owners

                      Top Institutional Owners

                      Mutual Fund Name

                      Institution Name

                      • Mutual Fund Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Eagle Small Cap Growth Fund

                      •  

                        1,258,892

                      • 2.44

                      • 3.00

                      • Fidelity® Select Biotechnology Portfolio

                      •  

                        903,303

                      • 0.00

                      • 2.15

                      • SPDR® S&P Biotech ETF

                      •  

                        715,478

                      • 3.60

                      • 1.91

                      • Oppenheimer Global Opportunities

                      •  

                        600,000

                      • 315.46

                      • 1.43

                      • iShares Nasdaq Biotechnology

                      •  

                        557,463

                      • -0.69

                      • 1.49

                      • Vanguard Total Stock Mkt Idx

                      •  

                        529,145

                      • 2.55

                      • 1.26

                      • iShares Russell 2000 (AU)

                      •  

                        512,935

                      • -1.02

                      • 1.37

                      • Loomis Sayles Small Cap Growth Fund

                      •  

                        408,061

                      • -2.47

                      • 0.97

                      • Vanguard Extended Market Index Fund

                      •  

                        394,238

                      • 33.62

                      • 0.94

                      • Hartford Healthcare Fund

                      •  

                        384,900

                      • 0.00

                      • 0.92

                      • Institution Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Wellington Management Company, LLP

                      •  

                        3,397,773

                      • -2.94%

                      • 8.11

                      • Baker Bros Advisors LLC

                      •  

                        3,248,043

                      • +4.93%

                      • 7.75

                      • GlaxoSmithKline PLC

                      •  

                        2,771,374

                      • 0.00%

                      • 6.62

                      • Eagle Asset Management, Inc.

                      •  

                        1,973,348

                      • +40.49%

                      • 4.70

                      • Palo Alto Investors, LLC

                      •  

                        1,661,612

                      • -47.15%

                      • 3.96

                      • Westfield Capital Management Company, LP

                      •  

                        1,659,070

                      • +45.72%

                      • 3.96

                      • VHCP Management, LLC

                      •  

                        1,545,999

                      • 0.00%

                      • 3.69

                      • Broadfin Capital, LLC

                      •  

                        1,443,220

                      • +44.20%

                      • 3.44

                      • Kingdon Capital Management LLC

                      •  

                        1,355,847

                      • +11.18%

                      • 3.23

                      • BlackRock Fund Advisors

                      •  

                        1,304,235

                      • +8.31%

                      • 3.11

                      Company Profile

                      Sector

                      Healthcare

                      Industry

                      Biotechnology

                      Type

                      Slow Growth

                      Style

                      Small Core

                      Anacor Pharmaceuticals Inc was incorporated in Delaware in December 2000 and began business operations in March 2002. It is a biopharmaceutical company engaged in discovering, developing and commercializing novel small-molecule thera...morepeutics derived from its boron chemistry platform. It has discovered, synthesized and developed eight molecules that are currently in development. The Company’s main product candidates include two topically administered dermatologic compounds, tavaborole (formerly referred to as AN2690) and AN2728. Tavaborole is a topical treatment for onychomycosis, a fungal infection of the nail and nail bed. AN2728 is its main topical anti-inflammatory product candidate for the treatment of atopic dermatitis and psoriasis, chronic inflammatory skin diseases that affect millions of peo...moreple. In addition, the Company has three other wholly-owned clinical product candidates; AN2718 and AN2898, which are backup compounds to tavaborole and AN2728, respectively, and AN3365 (formerly referred to as GSK2251052, or GSK '052), an antibiotic for the treatment of infections caused by Gram-negative bacteria, which previously was licensed to GlaxoSmithKline LLC (GSK). It has also discovered three other compounds that it has out-licensed for further development; one is licensed to Eli Lilly and Company (Lilly), for the treatment of an animal health indication; a second compound, AN5568, also referred to as SCYX-7158, is licensed to Drugs for Neglected Diseases initiative (DNDi), for human African trypanosomiasis (HAT, or sleeping sickness); and a third compound is licensed to GSK for tuberculosis (TB). As of February 1, 2014, the company was the owner of record, either solely or with a collaborator, of 23 issued U.S. patents. The Company and its third-party manufacturers are subject to periodic inspections of facilities by the FDA and other authorities, including procedures and operations used in the testing and manufacture of its products to assess its compliance with applicable regulations.lessless

                      Key People

                      Mr. Paul L. Berns

                      Chairman of the Board/Director/President/CEO

                      Dr. Lucy Shapiro PhD

                      Co-Founder/Director

                      Mr. Geoffrey M. Parker

                      CFO/Chief Accounting Officer/Executive VP

                      Vincent Ippolito

                      Executive VP/Other Executive Officer

                      Keith R. Leonard

                      Director

                      • Anacor Pharmaceuticals Inc

                      • 1020 East Meadow Circle

                      • Palo Alto, CA 94303-4230

                      • USA.Map

                      • Phone: +1 650 543-7500

                      • Fax: +1 650 543-7660

                      • anacor.com

                      Incorporated

                      2000

                      Employees

                      79

                      Send Feedback

                      We appreciate your input!

                      • I'm having trouble signing into my Microsoft account

                      • I’m having problems with the services stripe (Mail, Facebook, etc.)

                      • There is an issue with my weather information

                      • I see an error in the content

                      • Other

                      Please give an overall site rating: